Patents Assigned to Protagonist Therapeutics, Inc.
  • Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
    Patent number: 10196424
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: February 5, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Bourne, Ashok Bhandari, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • ?4?7 thioether peptide dimer antagonists
    Patent number: 10059744
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: August 28, 2018
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis
  • Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
    Patent number: 10035824
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: July 31, 2018
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Hepcidin analogues and uses thereof
    Patent number: 10030061
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: July 24, 2018
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
    Patent number: 10023614
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: July 17, 2018
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Hepcidin analogues and uses thereof
    Patent number: 9822157
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: November 21, 2017
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • ?4?7 peptide monomer and dimer antagonists
    Patent number: 9809623
    Abstract: The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against ?4?1 binding, and have high stability under gastrointestinal conditions.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: November 7, 2017
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Larry C. Mattheakis, David Liu
  • HEPCIDIN AND MINI-HEPCIDIN ANALOGUES AND USES THEREOF
    Publication number: 20170313754
    Abstract: The present invention provides novel hepcidin analogues, and related methods of using these hepcidin analogues to treat or prevent a variety of diseases and disorders, including iron overload diseases such as hereditary hemochromatosis, iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: June 29, 2015
    Publication date: November 2, 2017
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas BOURNE, Mark Leslie SMYTHE, Brian Troy FREDERICK, Simone VINK
  • a4B7 integrin thioether peptide antagonists
    Patent number: 9714270
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: July 25, 2017
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis
  • Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
    Patent number: 9624268
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease are described.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: April 18, 2017
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas Bourne, Ashok Bhandari, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • ?4?7 peptide dimer antagonists
    Patent number: 9273093
    Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: March 1, 2016
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
  • NOVEL A4B7 PEPTIDE ANTAGONISTS
    Publication number: 20140294902
    Abstract: The invention relates to disulfide-rich peptide molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 2, 2014
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
  • NOVEL A4B7 PEPTIDE DIMER ANTAGONISTS
    Publication number: 20140294901
    Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 2, 2014
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
  • NOVEL a4B7 PEPTIDE DIMER ANTAGONISTS
    Publication number: 20140193465
    Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Application
    Filed: October 10, 2013
    Publication date: July 10, 2014
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis